Page last updated: 2024-10-27

gabexate and Transposition of Great Vessels

gabexate has been researched along with Transposition of Great Vessels in 1 studies

Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Transposition of Great Vessels: A congenital cardiovascular malformation in which the AORTA arises entirely from the RIGHT VENTRICLE, and the PULMONARY ARTERY arises from the LEFT VENTRICLE. Consequently, the pulmonary and the systemic circulations are parallel and not sequential, so that the venous return from the peripheral circulation is re-circulated by the right ventricle via aorta to the systemic circulation without being oxygenated in the lungs. This is a potentially lethal form of heart disease in newborns and infants.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chihara, K1
Akiyama, F1
Shinozaki, T1
Shimamoto, M1
Takahashi, K1
Imura, H1
Yamazaki, F1
Kawarazaki, S1

Other Studies

1 other study available for gabexate and Transposition of Great Vessels

ArticleYear
[Disseminated intravascular coagulation (DIC) following open heart surgery and great vessel surgery. The result of early administration of gabexate mesilate (FOY)].
    Kyobu geka. The Japanese journal of thoracic surgery, 1984, Volume: 37, Issue:8

    Topics: Adolescent; Adult; Aged; Blood Transfusion; Cardiac Surgical Procedures; Coronary Disease; Dissemina

1984